readthroughSign in
Nov 16, 2026Weekly roundup

ViiV registers two HIV studies: DDI trial for VH4011499 and NIAID-led PALACE trial

ViiV Healthcare appears in two newly registered, not-yet-recruiting trials, one testing drug interactions for VH4011499 and one, led by NIAID, testing lenacapavir plus cabotegravir in people with viremia.

ViiV Healthcare is tied to two Phase 1 studies registered on November 16, 2026, both listed as not yet recruiting.

  • A ViiV-sponsored trial will test pharmacokinetic interactions between VH4011499 and a set of other drugs, including ritonavir, efavirenz, carbamazepine, metformin, digoxin, rosuvastatin, and pitavastatin, in HIV negative adults, also assessing safety and tolerability during co-administration.1 The study is listed with an estimated start of 2026-11-161 and an estimated enrollment of 75 participants.1
  • A separate trial called "PALACE" is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), with ViiV Healthcare and Gilead Sciences listed as collaborators.2 The single-arm, open-label Phase 1 study will evaluate long-acting lenacapavir plus cabotegravir in people with HIV-1 who have a history of treatment non-adherence and confirmed or suspected resistance to rilpivirine.2 It is listed with an estimated start date of 2028-02-012 and an estimated enrollment of 38 participants.2

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.